More recent studies have suggested potential synergistic activity of HDAC inhibitors and DNMT inhibitors using preclinical models of PTCL [108, 109], and that the combination of both epigenetic targeting agents romidepsin and azacytidine may be a particularly effective treatment strategy in PTCL. The gene discussed is DNMT1; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.